FENHIL
FINERENONE · by HILTON
Composition
Tab 10 mg/20 mg: Finerenone 10 mg/20 mg.
Indications & Dosage
Chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes: Adult: If serum-potassium 5 mmol/L and eGFR _60 mL/min/1.73 m2: 20 mg once daily. If serum-potassium 5 mmol/L and eGFR 25 to 59 mL/min/1.73 m2: Initially 10 mg once daily; increased if necessary up to 20 mg once daily, dose to be adjusted according to serum-potassium levels and eGFR, for details on dose adjustments, interruption, and discontinuation consult product literature.
Contraindications
Addison’s disease, hyperkalaemia; do not initiate treatment if serum-potassium > 5 mmol/L. Withhold if serum-potassium increases to > 5.5 mmol/L during treatment.
Precautions
Avoid in severe hepatic impairment; consider additional serum-potassium monitoring in moderate impairment. In renal impairment, avoid initiation if eGFR less than 25 mL/minute/1.73 m2, discontinue if eGFR falls persistently below 15 mL/minute/1.73 m2 (end-stage renal disease) during treatment. Measure serum-potassium and eGFR at baseline; if serum-potassium > 4.8 to 5 mmol/L at initiation, additional monitoring of serum-potassium required during first 4 weeks of treatment. Remeasure serum-potassium and eGFR 4 weeks after initiation or when restarting treatment or increasing dose.
Interactions
ACE inhibitors, angiotensin II antagonists, potassium sparing diuretics, potassium supplements, NSAIDs.
Pregnancy
Avoid unless potential benefit outweighs risk
Lactation
Avoid unless potential benefit outweighs risk
Side Effects
Headache,constipation, cough, diarrhoea, dizziness, hyperkalaemia, hypotension, muscle spasm, musculoskeletal pain,nausea, syncope, flatulence, vomiting, rash, postural hypotension, arterial thrombosis, dyslipidaemia, insomnia, dehydration, asthenia, malaise, sweating and pruritus.